Phase 1 Study of Oral TP-1454

Status Active, not recruiting

Clinical Trial Summary

This study will evaluate the safety and tolerability of oral TP-1454 in patients with advanced metastatic or progressive solid tumors and anal cancer.

Clinical Trial Description

Primary Objective: • To establish the MTD and/or Recommended Phase 2 Dose (RP2D) of orally administered TP-1454 in patients with metastatic solid tumors and anal cancer. Secondary Objectives: - To establish the pharmacokinetic (PK) profile of orally administered TP-1454 - To observe patients for any evidence of antitumor activity of TP 1454 by objective radiographic assessment - To assess the safety and tolerability of TP-1454 ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04328740
Study type	Interventional
Source	Sumitomo Pharma America, Inc.
Contact
Status	Active, not recruiting
Phase	Phase 1
Start date	July 8, 2020
Completion date	October 31, 2024

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT06223308` - A Study Evaluating the Safety and Efficacy of HB0028 in Subjects With Advanced Solid Tumors	Phase 1/Phase 2
Not yet recruiting	`NCT05515185` - B7-H3 Targeting CAR-T Cells Therapy for B7-H3 Positive Solid Tumors	Early Phase 1
Completed	`NCT05508100` - Dose Confirmation and Dose Expansion Phase 1 Study of IO-108 and IO-108 + Anti-PD-1 in Solid Tumors	Phase 1
Recruiting	`NCT05094804` - A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents	Phase 1/Phase 2
Completed	`NCT02836600` - A Study of LY3039478 in Japanese Participants With Advanced Solid Tumors	Phase 1
Recruiting	`NCT04890613` - Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation	Phase 1
Recruiting	`NCT04390737` - Evaluate the Safety and Clinical Activity of HH2853	Phase 1/Phase 2
Recruiting	`NCT06007482` - A Study of ES009 in Subjects With Locally Advanced or Metastatic Solid Tumors	Phase 1
Recruiting	`NCT05981703` - A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors	Phase 1
Completed	`NCT04108676` - Effect of Omeprazole on PK of Fluzoparib in Healthy Male Subjects	Phase 1
Recruiting	`NCT05798611` - Study of ART0380 in Patients With Biologically Selected Solid Tumors	Phase 2
Recruiting	`NCT05076396` - PM14 Administered Intravenously to Patients With Advanced Solid Tumors	Phase 1
Recruiting	`NCT06008366` - A Phase 1/2 Study of 7MW3711 in Advanced Solid Tumors	Phase 1/Phase 2
Recruiting	`NCT06054932` - Safety, Tolerability, and Immunogenicity of LK101 Alone in Participants With Incurable Solid Tumors	Phase 1
Recruiting	`NCT04825392` - A Phase Ib Study of HX008 in Patients With Advanced Solid Tumors	Phase 1
Active, not recruiting	`NCT04242199` - Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors	Phase 1
Not yet recruiting	`NCT06365918` - Study of VG2025 Delivered Intraperitoneally in Patients With Advanced Solid Tumors With Carcinomatosis	Phase 1
Recruiting	`NCT05461287` - Safety, Tolerability and Pharmacokinetics Study of QLS31904 in Patients With Advanced Solid Tumors	Phase 1
Recruiting	`NCT05569057` - A Phase I Trial of SIM1811-03 in Subjects With Advanced Solid Tumors and Cutaneous T-cell Lymphoma	Phase 1
Recruiting	`NCT05443126` - A Study of EP0031 in Patients With Advanced RET-altered Malignancies	Phase 1/Phase 2